Pharmaceutical Technology

AUGUST 23, 2022

It comprises messenger ribonucleic acid (mRNA) that encodes for the initial spike protein of SARS-CoV-2 along with mRNA that encodes for Omicron BA.4/BA.5 5 variant spike protein. The companies have also commenced rolling submission for conditional marketing authorization from the European Medicines Agency (EMA) for this Omicron BA.4/BA.5-adapted

Vaccination 130

Vaccination Vaccine Gene Therapy Protein 130

Pharmaceutical Technology

NOVEMBER 9, 2022

CSL Behring has a commercialisation and license agreement to develop EtranaDez. Haemophilia A is caused by insufficient levels of the clotting protein factor VIII, while patients with haemophilia B lack adequate factor IX levels. A fair price for CSL Behring’s haemophilia B treatment etranacogene dezaparvovec would be between $2.93–2.96

Gene Therapy 278

Gene Therapy Gene FDA Approval Medicine 278

pharmaphorum

JANUARY 21, 2021

This is the first project to be funded by the international Psychiatry Consortium, a £4 million collaboration between seven global pharmaceutical companies, and two leading research charities, convened and managed by the Medicines Discovery Catapult, that supports high-value drug discovery projects in this area of unmet patient need.

Medicine 111

Medicine Protein Drugs Research 111

pharmaphorum

JULY 8, 2022

Swedish rare disease specialist Sobi is paying $55 million upfront to license rights to ADC Therapeutics’ lymphoma therapy Zynlonta – approved in the US last year – in Europe and other international markets. The post Sobi bolsters blood division via $435m ADC licensing deal appeared first on.

Licensing 52

Licensing Licensing Sales Marketing 52

pharmaphorum

JANUARY 11, 2023

Anima uses its mRNA Lightning platform to discover small molecules and determine their mechanisms of action for diseases previously deemed undruggable, with scientists searching for compounds that target proteins with roles in regulating mRNA, so as to affect disease states through post-transcriptional regulation (i.e.

Protein 105

Protein Regulation FDA Approval Licensing 105

The Pharma Data

JANUARY 6, 2021

CAMBRIDGE, England & WETHERBY, England–( BUSINESS WIRE )– Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer ® and pre|CISION platforms, is pleased to announce that it has entered into a license agreement with POINT Biopharma Inc.

Licensing 52

Licensing Licensing Development Clinical Trials 52

The Pharma Data

OCTOBER 27, 2021

NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433. synuclein protein, mainly in oligodendroglial cells (glial cytoplasmic inclusions) and also in certain nerve cells.

Licensing 52

Licensing Licensing Drugs Development 52

Pfizer

SEPTEMBER 28, 2022

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5-Adapted Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5-Adapted 5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age. Tue, 09/27/2022 - 16:15. Wednesday, September 28, 2022 - 11:45am.

Vaccination 101

Vaccination Vaccine Medicine Clinical Trials 101

Drug Discovery Today

APRIL 22, 2020

Cambridge, UK, and Brisbane, CA, 21 April 2020 Mogrify Ltd (Mogrify®), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, and Sangamo Therapeutics (Sangamo) (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a collaboration and exclusive license (..)

Licensing 40

Licensing Licensing Genome Genomics 40

pharmaphorum

DECEMBER 21, 2021

The US biotech’s other main platform is XTEN, which adds side chains to existing molecules to extend their activity in the body and prevent off-target effects, and has already been licensed to other drugmakers including Biogen and Merck & Co. Sanofi’s other acquisitions this year were the $3.2 billion upfront.

Licensing 124

Licensing Licensing Protein Clinical Development 124

pharmaphorum

MARCH 8, 2021

The EMA’s human medicines committee has said two Eli Lilly antibodies are effective in people with COVID-19 who are at risk of developing severe disease, clearing the way for use in EU member states.

Antibody 105

Antibody Licensing Licensing Protein 105

pharmaphorum

JULY 5, 2022

Cell therapy specialist Mogrify has struck a deal with Japanese drugmaker Astellas to look at ways to deploy regenerative medicine to treat hearing loss caused by factors such as chronic exposure to loud noises. An estimated 1.57

In-Vivo 110

In-Vivo Bioinformatics Genetics Licensing 110

The Pharma Data

SEPTEMBER 8, 2020

Fourteen newly licensed medicines have been accepted for use on NHS Scotland by the Scottish Medicines Consortium (SMC), bringing a raft of new treatment options for conditions including epilepsy, depression and cancer.

Medicine 52

Medicine Clinical Trials Clinical Trials Drugs 52

pharmaphorum

OCTOBER 3, 2022

DMD is a severe, progressive muscle-wasting genetic condition caused by the lack of a protein called dystrophin. Translarna was the first licensed treatment for DMD which addresses the loss of dystrophin. Eventually, they will need assistance with breathing.

Gene Therapy 98

Gene Therapy Gene FDA Approval DNA 98

pharmaphorum

JANUARY 3, 2023

SPK-9001 is a novel, investigation vector containing a bio-engineered adeno-associated virus (AAV) capsid (protein shell) and a high-activity human coagulation FIX gene. Additional key data is to be presented at scientific conference early this year.

Gene Therapy 98

Gene Therapy Gene Medicine Trials 98

pharmaphorum

SEPTEMBER 13, 2022

.” If Lamzede is approved by the FDA, it will be another milestone for Chiesi’s two-year-old rare disease division , based in Boston, which was formed to diversify away from the company’s traditional focus on respiratory medicines and further its ambition to grow in the US.

Drugs 105

Drugs Licensing Licensing Production 105

The Pharma Data

AUGUST 17, 2020

. (“Dragonfly”), today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted the global exclusive license to Dragonfly’s interleukin-12 (IL-12) investigational immunotherapy program, including its extended half-life cytokine DF6002. About Bristol Myers Squibb.

Licensing 52

Licensing Licensing Development Production 52

The Pharma Data

JUNE 14, 2023

Cedilla’s small molecules conditionally modulate the protein complex in its functional state resulting in highly selective inhibition. Cedilla will also be eligible to receive royalties on medicines based on their technology commercialized by Bayer. Financial details have not been disclosed.

Licensing 40

Licensing Licensing Life Science Development 40

The Pharma Data

DECEMBER 13, 2020

Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicines company transforming the drug discovery process with the goal of bringing life-changing therapies to patients. . CAMBRIDGE, Mass., 14, 2020 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements.

Licensing 40

Licensing Licensing Clinical Trials Clinical Trials 40

Pharmaceutical Technology

APRIL 24, 2023

Everest Medicines launched its immunoglobulin A (IgA) nephropathy drug Tarpeyo (Nefecon) (budesonide) in China’s Hainan Boao Pilot Zone, making it the first therapy available in this disease area. The China National Medical Products Administration (NMPA) accepted Everest Medicines’ New Drug Application for Tarpeyo in November 2022.

Drugs 130

Drugs Medicine Production Marketing 130

pharmaphorum

JULY 18, 2022

“It is programmed and coded for the production of the full-length spike protein of the coronavirus. It then elicits an immune response against that spike protein. We’ve been inspected by the European Medicines Agency (EMA) and passed the Good Manufacturing Practice (GMP) inspection.

Vaccination 138

Vaccination Vaccine Development Immune Response 138

XTalks

APRIL 3, 2024

The RBCs in circulation are marked by proteins in the complement system for removal by the spleen and liver. Through its Alexion deal, AstraZeneca is looking to expand into other rare diseases, including various forms of amyloidosis for which it has secured licensing deals and buyouts.

FDA Approval 102

FDA Approval Sales Trials Development 102

The Pharma Data

JANUARY 5, 2021

Targeting RNA is believed to be a way to develop therapeutics for so-called undruggable proteins. This is because many proteins do not have small-molecule binding sites. So therapeutics that focus on RNA are designed to stop the DNA from coding for disease-causing proteins.

RNA 52

RNA Protein Bioavailability DNA 52

pharmaphorum

SEPTEMBER 28, 2020

Privately-held biotech Galecto has raised $64m with an equity funding round to further research into treatments for drugs including a potential inhaled idiopathic pulmonary fibrosis (IPF) medicine. The funding could also help to advance its pipeline of other fibrosis and cancer medicines, the company said.

Drugs 59

Drugs Licensing Licensing Medicine 59

pharmaphorum

DECEMBER 22, 2020

GlaxoSmithKline has closed the year with a flurry of deals, leaving its development pipeline bulging like Santa’s sack as chief scientific officer Hal Barron pursues a strategy to develop “transformational medicines”. The antibody targets PVRIG, an inhibitory protein expressed on natural killer cells (NK cells) and T-cells.

Licensing 52

Licensing Licensing Genetics Sales 52

Velocity Clinical Research

AUGUST 8, 2024

The presence of amyloid proteins has been known since the disease was named, and the initial thinking was that their build-up caused it. We understand the tau protein, that some people have inflammation in the brain or a genetic predisposition. But now we know it’s not just that,” explains Dr. Cupelo. “We

Clinical Trials 105

Clinical Trials Clinical Trials Genetics Clinical Research 105

The Pharma Data

SEPTEMBER 20, 2020

20, 2020 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that updated data from the full Phase 1 cohort of the CodeBreaK 100 clinical study, evaluating sotorasib (proposed INN for AMG 510) in 129 patients across multiple advanced solid tumors, were published in the New England Journal of Medicine (NEJM). THOUSAND OAKS, Calif.

Medicine 52

Medicine Production Sales Clinical Trials 52

pharmaphorum

APRIL 7, 2021

In its second licensing deal in the radio-oncology area in consecutive weeks, Novartis has agreed a $1.3 billion-plus alliance with UK biotech Artios Pharma to develop precision medicines for cancer. billion licensing deal, and is due to filed for regulatory approval in the US and EU this year.

DNA 52

DNA Licensing Licensing Gene Therapy 52

The Pharma Data

NOVEMBER 30, 2020

1, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”, NYSE: BHVN). GPCR – G protein-coupled receptors. . TOKYO and CAMBRIDGE, England , Dec.

Licensing 40

Licensing Licensing Production Development 40

pharmaphorum

JANUARY 12, 2021

But with new technology based on branched silencing RNA licensed from the University of Massachusetts Medical School, Atalanta says it could change this. There’s also a connection with Greek mythology from the name of the protein that is targeted by the RNAi drug in Huntington’s – Argonaute 2.

RNA 95

RNA Production Development Pharma Companies 95

Druggist

FEBRUARY 17, 2021

Hydrocortisone cream is classified as pharmacy-only medicine (P), which means it can only be sold in pharmacies, including online chemists and sellers on Amazon.co.uk. Anthisan Cream contains a medicine called mepyramine maleate. Lanacane is licensed for adults and children from 12 years of age. 822 Reviews. Price incl.

Pharmacy 98

Pharmacy Containment Production Sales 98

The Pharma Data

DECEMBER 17, 2020

NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , 17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Medicine Production Trials 52

The Pharma Data

MARCH 14, 2021

This is much lower than would be expected to occur naturally in a general population of this size and is similar across other licensed COVID-19 vaccines. The monthly safety report will be made public on the European Medicines Agency website in the following week, in line with exceptional transparency measures for COVID-19.

Vaccination 52

Vaccination Vaccine Licensing Licensing 52

The Pharma Data

MAY 2, 2022

– Gilead to License Exclusive Worldwide Rights to the Investigational Candidate DF7001, a 5T4-Targeting NK Cell Engager for Solid Tumors –. – Gilead to Have Options to License Several Additional NK Cell Engager Programs –. Gilead Sciences, Inc. View the full release here: [link]. Gilead Sciences, Inc.

Development 52

Development Research Licensing Licensing 52

pharmaphorum

MAY 13, 2022

According to BridgeBio and other SHP2 developers like Revolution Medicines, Jacobio, Erasca, Redx Pharma and Relay Therapeutics, the phosphatase enzyme – once considered “undruggable” – is over-expressed in a number of different solid tumour types. The post BMS doubles down on BridgeBio alliance on SHP2 drugs appeared first on.

Drugs 59

Drugs Pharma Companies Medicine Licensing 59

The Pharma Data

NOVEMBER 17, 2020

Lead Pharma has entered into a collaboration and license agreement with Roche , hoping to lead the way in the development of oral small molecules for immune-mediated diseases like rheumatoid arthritis, psoriasis and inflammatory bowel diseases. .

Immune Response 52

Immune Response Licensing Licensing Sales 52

Delveinsight

AUGUST 13, 2020

The researchers cite data in the New England Journal of Medicine, showing Black Americans account for a disproportionate number of COVID-19 cases in the U.S. The licensing agreement comes almost two years after Roche dropped the tumor microenvironment modulator after putting it through a clutch of early-phase studies in solid tumor patients.

Trials 52

Trials Research Drugs Protein 52